GRL-0617 is primarily researched for its potential as an antiviral agent, particularly in the treatment of infections caused by coronaviruses. It functions as a papain-like protease (PLpro) inhibitor, which is crucial for the replication and spread of certain viruses. By inhibiting PLpro, GRL-0617 disrupts the virus's ability to evade the host immune response and replicate within host cells. This makes it a promising candidate for developing treatments against diseases like SARS and COVID-19. Additionally, its mechanism of action is being studied for broader applications in combating other viral infections where PLpro plays a significant role. Ongoing research focuses on optimizing its efficacy and safety for potential therapeutic use.